Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 9/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.35 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599336 | 0.77 | PGR (0.69) | PGRHPGDLMNAAR | |
| SCHEMBL4790986 | 0.70 | PGR (0.61) | PGRHPGDKIF11ARNR1H2 | |
| SCHEMBL4599337 | 0.69 | HPGD (0.51) | PGRHPGDLMNANR3C2KIF11 | |
| SCHEMBL4611480 | 0.66 | PGR (1.00) | PGRAR | |
| SCHEMBL6727738 | 0.66 | PGR (0.58) | PGRHPGDLMNANR3C2KIF11 | |
| SCHEMBL5132601 | 0.65 | PGR (0.74) | PGRHPGDLMNAKIF11AR | |
| SCHEMBL4612707 | 0.65 | PGR (0.67) | PGRHPGDLMNAKIF11AR | |
| SCHEMBL4598912 | 0.64 | PGR (0.74) | PGRHPGDLMNAKIF11AR | |
| SCHEMBL5344146 | 0.64 | NR1H2 (0.45) | PGRHPGDLMNANR3C2KIF11 | |
| SCHEMBL28549758 | 0.64 | CA1 (0.61) | PGRHPGDLMNANR3C2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910285-A1 | CYANOPYRROLE-SULFONAMIDE PROGESTERONE RECEPTOR MODULATORS AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7291643-B2 | Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof | WYETH (US) | 2007-11-06 | — | — | US | disclosed |
| WO-2007016212-A1 | CYANOPYRROLE-SULFONAMIDE PROGESTERONE RECEPTOR MODULATORS AND USES THEREOF | WYETH (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027201-A1 | Use of progesterone receptor modulators | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027126-A1 | E.g., N-[4-(5-cyano-1-methyl-1H-pyrrol-2-yl)phenyl]propane-1-sulfonamide and tert-butyl 2-cyano-5-{4-{(ethylsulfonyl)amino]phenyl}-1H-pyrrole-1-carboxylate; useful for contraception and hormone replacement therapy | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027201-A1 | Use of progesterone receptor modulators | GNRHR, PGR, FSHR | PGR 2/4885HPGD 358/4885LMNA 1341/4885 |
| US-20070027126-A1 | E.g., N-[4-(5-cyano-1-methyl-1H-pyrrol-2-yl)phenyl]propane-1-sulfonamide and tert-butyl 2-cyano-5-{4-{(ethylsulfonyl)amino]phenyl}-1H-pyrrole-1-carboxylate; useful for contraception and hormone replacement therapy | GNRHR, PGR, PRLHR | PGR 2/4885HPGD 736/4885LMNA 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.